

Concord Biotech Ltd

Scaling global fermentation-based API







Kyon ki bhaiya, sabse bada rupaiya.

Concord Biotech Ltd

Subscribe at upper price band of INR 741

Scaling global fermentation-based API

Concord Biotech Limited (CBL) was incorporated on November 23, 1984. Concord is an India-based biopharma company and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022, supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India. Concord is amongst the few companies globally that have successfully and sustainably established and scaled up fermentation-based API manufacturing capabilities

In 2022, Concord commanded a market share of over 20% in fermentation-based API products, including mupirocin, sirolimus, tacrolimus, mycophenolate sodium, and cyclosporine. As of March 31, 2023, Concord's fermentation capacity reached 1,250 m³. They expanded their formulation business to India and emerging markets like Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore, and Paraguay. They further expanded to the United States.

Concord has a strong presence in the rapeutic areas and is well-positioned to benefit from industry growth. In India, Concord markets 27 brands of immunosuppressants, nephrology drugs, and anti-infective drugs for critical care. Their sales team operates in 20 states and 5 union territories. They also supply immunosuppressants to the Indian market through a B2B contract development manufacturing organization (CDMO) business.

Concord's clientele extends to over 200 customers in more than 70 countries for both APIs and formulations, with long-term supply agreements with some of them. Notably, Intas Pharmaceuticals Ltd and Glenmark Pharmaceuticals Ltd are among their API customers.

At the IPO price of INR 741 (upper price band), CBL is valued at P/E of 32.3x. Considering the growth opportunities in the company and strong fundamentals, we recommend a SUBSCRIBE rating

Industry	Pharmaceutical
Issue Details	
Listing	BSE & NSE
Open Date	4 th Aug 2023
Close Date	8 th Aug 2023
Price Band	INR 705-741
Face Value	INR 1
Market Lot	20 shares
Minimum Lot	1 Lot

Issue Structure							
Offer for Sale	100%						
Fresh Issue	0%						
Issue Size (Amt)	INR 1,551 cr						
Issue Size (Shares)	2,09,25,652						
QIB Share (%)	≤ 50%						
Non-Inst Share (%)	≥ 15%						
Retail Share (%)	≥ 35%						
Pre issue sh (nos)	104616204						
Post issue sh (nos)	104616204						
Post issue M Cap	7,752 cr						

Shareholding (%)	Pre	Post
Shareholanig (70)	(%)	(%)
Promoter	44.08	44.08
Public- Helix Investment	20.00	0.0
Public	35.92	55.92
TOTAL	100	100

Key Financial Data (INR Cr, unless specified)

			EBITDA	PAT	Adj EPS	BVPS	RoE	RoiC	EV/EBITDA	P/E	
	Revenue	EBITDA PAT	EBIIDA PAI	(%)	(%)	(₹)	(₹)	(%)	(%)	(%)	(X)
FY21	616.9	327.9	235.3	53.2	38.1	22.5	95.6	23.5	33.0	23.4	32.9
FY22	712.9	273.9	178.6	38.4	25.0	16.7	105.5	15.9	21.8	28.0	44.3
FY23	853.1	343.3	238.2	40.2	27.9	23.0	123.3	18.6	25.4	22.1	32.3





Issue Structure and Offer Details

The proposed fresh issue size of SBFC is INR 1,551 cr(Pure OFS) and the price band for the issue is in the range of INR 705-741 and the bid lot is 20 shares and multiples thereof.

Issue Structure					
Investor Category	Allocation	No. of shares offered			
QIB	Not more than 50% of the Offer	1,04,57,825			
NIB	Not less than 15% of the Offer	31,37,348			
Retail	Not less than 35% of the Offer	73,30,479			
Number of shares based on a high	gher price band of INR 741				

Source: Company Reports

Details	of the	selling	share	holders
---------	--------	---------	-------	---------

Promoter Selling shares	Amount offered	No of shares
Helix Investment Holdings Pte Ltd	Not more than 1,551 Cr	2,09,25,652
The amount is based on a higher price band o		

Source: Company Reports



CBL financial summary	and analysis	
------------------------------	--------------	--

Pign INR Cr (unless spaceliked) Piz1 Piz2 Piz3 Pign INR Cr (unless spaceliked) Piz1 Piz2 Pi			DE IIIIaii	iai saiiiii	iary and analysis			
New Note	Fig in INR Cr (unless specified)	FY21	FY22	FY23	Fig in INR Cr (unless specified)	FY21	FY22	FY23
	Income Statement				Per share data & Yields			
Raw Material Cost 11.1.6 16.0.4 18.0.2 Adjusted EVPS (INR) 15.5 10.5.5 10.5.6 RM Cost to Sales (%) 18.1 23.0 21.1 Adjusted ECP per share (INR) 15.9 19.9 23.5 Employee Cost to Sales (%) 11.3 13.4 12.9 Adjusted FCP per share (INR) (1.2) (0.3) 2.2 2.7 3.2 Employee Cost to Sales (%) 17.5 25.2 25.1 EERITOA 18.9 24.1 FCF Yeld (%) (0.2) (0.0) 0.0 Other Exporases 18.0 12.5 25.5 25.1 Selectify (1.0) 0.0 0.0 BBTOA 20.0 18.2 24.8 40.9 Total Debt to Equity 0.1 <td>Revenue</td> <td>616.9</td> <td>712.9</td> <td>853.2</td> <td>Adjusted EPS (INR)</td> <td>22.5</td> <td>16.7</td> <td>16.7</td>	Revenue	616.9	712.9	853.2	Adjusted EPS (INR)	22.5	16.7	16.7
RM Cast to Sales (%) 18.1 23.0 21.1 Adjusted CFO per share (INR) 15.9 15.9 23.5 Employee Cost to Sales (%) 11.3 31.4 12.9 Adjusted FCF per share (INR) (1.2) (0.2) 0.3 2.2 Other Expenses 108.0 17.9 22.5 25.5 25.5 25.5 17.5 17.5 18.0 0.0	YoY Growth (%)	20.4	15.6	19.7	Adjusted Cash EPS (INR)	25.1	21.5	21.9
Employee Cost 695 95,7 110.3 CFO Yield (%) 2.2 2.7 3.2 2.2 Chrore Cost to Soles (%) 113 13.4 12.9 Adjusted FCF per share (INR) (1.2) (0.3) 2.2 Content Expresses 108.0 17.5 2.2 25.1 Expresses 108.0 17.5 2.2 25.1 Expresses 108.0 17.5 25.2 25.1 Expression (INR) 10.2 (0.3) 0.0 0.	Raw Material Cost	111.6	164.0	180.2	Adjusted BVPS (INR)	95.5	105.5	105.6
Employee Cost to Soles (%)	RM Cost to Sales (%)	18.1	23.0	21.1	Adjusted CFO per share (INR)	15.9	19.9	23.5
Other Expenses 108.0 17.3 214.1 b FCF Yield (%) (0.2) (0.0) 0.3 Other Exp to Soles (%) 17.5 7.5 25.2 b 25.1 b Solement Report Soles (%) 0.01 0.01 0.01 BBIT Margin (%) 53.2 38.4 d 40.9 d 70.40 deported the fequity 0.1 0.1 0.1 0.1 0.1 0.0 EBIT Sole (%) 60.3 (16.5 d 50.5 54.0 d Perbet to Equity 0.1 0.1 0.1 0.1 0.1 0.0 BORGIN (%) 48.7 d 31.4 d 34.5 d 34.5 d Step the bet to Equity 0.1 0.1 0.0 <td>Employee Cost</td> <td>69.5</td> <td>95.7</td> <td>110.3</td> <td>CFO Yield (%)</td> <td>2.2</td> <td>2.7</td> <td>3.2</td>	Employee Cost	69.5	95.7	110.3	CFO Yield (%)	2.2	2.7	3.2
Part	Employee Cost to Sales (%)	11.3	13.4	12.9	Adjusted FCF per share (INR)	(1.2)	(0.3)	2.2
BRITIOA 32.7.9 32.8.9 40.9.9 Column (%) 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 <td>Other Expenses</td> <td>108.0</td> <td>179.3</td> <td>214.1</td> <td>FCF Yield (%)</td> <td>(0.2)</td> <td>(0.0)</td> <td>0.3</td>	Other Expenses	108.0	179.3	214.1	FCF Yield (%)	(0.2)	(0.0)	0.3
Morgin (%)	Other Exp to Sales (%)	17.5	25.2	25.1				
Por Growth (%)	EBITDA	327.9	273.9	348.6	Solvency Ratio (X)			
Depreciation & Amortization 27.5 50.1 54.0 Net Debt to EBITDA (0.3) (0.3	Margin (%)	53.2	38.4	40.9	Total Debt to Equity	0.1	0.1	0.1
Ref	YoY Growth (%)		(16.5)	27.3		(0.1)	(0.1)	(0.1)
Margin (%)	Depreciation & Amortization	27.5	50.1	54.0	Net Debt to EBITDA	(0.3)	(0.3)	(0.3)
YoY Growth (%) 63.9 (25.5) 31.6 Return on Equity 23.5 15.9 15.8 Other Income 13.8 23.4 35.3 Return on Capital Employed 20.3 13.9 18.8 Finance Cost 1.0 6.1 9.8 Return on Invested Capital 33.1 21.8 29.9 Interest Coverage (X) 286.9 36.5 30.0 Return on Invested Capital 33.1 21.8 29.9 PBT 313.2 241.2 320.1 Payable Days (Nos) 27 43 36 Morgin (%) 46.7 (23.0) 32.7 Receivable Days (Nos) 105 119 117 Tax Rexpense 77.8 62.6 81.9 Net Working Capital Days (Nos) 105 119 117 Tax Rexpense 77.8 62.6 81.9 Net Working Capital Days (Nos) 105 119 117 Tax Rexpense 77.8 175.0 27.9 Valuation (X) 105 119 117 Tax Expense 77.8	EBIT	300.4	223.9	294.5				
Other Income 13.8 23.4 35.3 Return on Capital Employed 20.3 13.9 18.8 Finance Cost 1.0 6.1 9.8 Return on Invested Capital 33.1 21.8 29.9 Interest Coverage (X) 28.6 36.5 30.0 Return on Invested Capital 33.1 21.8 29.9 PBT 313.2 241.2 320.1 Payable Days (Nos) 91 100 83 Yo' Growth (%) 46.7 (23.0) 32.7 Receivable Days (Nos) 105 119 117 Tax Rate (%) 46.7 24.9 26.0 25.6 25.6 25.6 Net Working Capital Days (Nos) 169 176 165 Tax Rate (%) 38.1 25.0 22.9 Net Working Capital Days (Nos) 169 165 165 Yo' Growth (%) 38.1 25.0 22.9 Youltainer (X) Youltaine	Margin (%)	48.7	31.4	34.5	Return Ratios (%)			
Finance Cost 10 6.1 9.8 Return on Invested Capital 33.1 21.8 29.9 Interest Coverage (X) 286.9 36.5 30.0 Exceptional Item 0.0 0.0 0.0 PBT 313.2 241.2 320.1 Payable Days (Nos) 9.1 100 8.3 Morgin (%) 50.8 33.8 37.5 Inventory Days (Nos) 9.1 100 10.5 Tox Expense 77.8 62.6 81.9 Net Working Capital Days (Nos) 169 176 16.5 Tox Rate (%) 24.9 26.0 81.9 Net Working Capital Days (Nos) 169 176 16.5 Tox Rate (%) 38.1 25.0 27.9 Net Working Capital Days (Nos) 169 176 16.5 Morgin (%) 38.1 25.0 27.9 Net Working Capital Days (Nos) 169 176 16.5 Morgin (%) 38.1 25.0 27.9 Net Working Capital Days (Nos) 169 176 16.5 Morgin (%) 38.1 25.0 27.9 Net Working Capital Days (Nos) 169 176 16.5 Morgin (%) 38.1 25.0 27.9 Net Working Capital Days (Nos) 169 176 16.5 Morgin (%) 38.1 25.0 27.9 Net Working Capital Days (Nos) 169 176 16.5 Morgin (%) 38.1 25.0 27.9 Net Working Capital Days (Nos) 169 176 176 Morgin (%) 38.1 25.0 27.9 Net Working Capital Days (Nos) 169 176 176 Morgin (%) 38.1 25.0 27.9 Net Working Capital Days (Nos) 169 176 176 Nor Work (%) 38.1 25.0 27.9 Net Working Capital Days (Nos) 169 176 176 Nor Work (%) 38.1 25.0 27.9 Net Working Capital Days (Nos) 169 176 176 Nor Work (%) 38.1 25.0 27.9 Net Working Capital Days (Nos) 169 176 176 Nor Work (%) 38.1 25.0 27.9 Net Working Capital Days (Nos) 169 176 176 Nor Work (%) 38.1 25.0 27.9 Net Working Capital Days (Nos) 169 176 176 Nor Work (%) 38.1 25.0 27.9 Net Working Capital Days (Nos) 169 176 176 Nor Work (%) 38.1 25.0 27.9 Net Working Capital Days (Nos) 170 1	YoY Growth (%)	63.9	(25.5)	31.6	Return on Equity	23.5	15.9	15.8
Interest Coverage (X)	Other Income	13.8	23.4	35.3	Return on Capital Employed	20.3	13.9	18.8
Exceptional Item 0.0 0.0 0.0 Working Capital Ratios PBT 313.2 241.2 320.1 Payable Days (Nos) 27 43 36 Morgin (%) 50.8 33.8 37.5 Inventory Days (Nos) 91 100 83 Yor Growth (%) 46.7 (23.0) 32.7 Receivable Days (Nos) 105 119 117 Tax Expense 77.8 62.6 81.9 Net Working Capital Days (Nos) 169 176 165 Tox Rate (%) 24.9 26.0 25.6 Net Working Capital Days (Nos) 169 176 165 PAT 235.3 178.6 238.1 Net Working Capital Days (Nos) 169 176 165 Margin (%) 38.1 25.0 27.9 Valuation (X) Net Working Capital Days (Nos) 168 44.3 44.3 45.2 PAT 235.3 175.0 18.5 48.2 49.5 44.3 44.3 44.3 44.3 44.3 44.3 44.3	Finance Cost	1.0	6.1	9.8	Return on Invested Capital	33.1	21.8	29.9
PBT 313.2 241.2 320.1 Payable Days (Nos) 2.7 4.3 3.6 Morgin (%) 50.8 33.8 37.5 Inventory Days (Nos) 91 100 83 YOY Growth (%) 46.7 (23.0) 3.27 Recivable Days (Nos) 105 119 117 Tax Expense 77.8 62.6 81.9 Net Working Capital Days (Nos) 169 176 165 Tox Rate (%) 24.9 26.0 25.6 Net Working Capital Days (Nos) 169 176 165 PAT 235.3 178.6 238.1 25.0 27.9 Valuation (X) 46.2 48.3 45.2 YOY Growth (%) 39.3 (24.1) 33.4 P/E 32.9 44.3 44.3 43.3 Morgin (%) 38.1 24.5 20.5 P/BW 2.3 2.0 2.1 4.0 2.1 4.0 2.1 4.0 2.1 4.0 2.1 4.0 2.1 4.0 2.1 2.0 2.	Interest Coverage (X)	286.9	36.5	30.0				
Margin (%) 50.8 33.8 37.5 Inventory Days (Nos) 91 100 83 YOY Growth (%) 46.7 (23.0) 32.7 Receivable Days (Nos) 105 119 117 Tax Expense 77.8 62.6 81.9 Net Working Capital Days (Nos) 169 165 165 Tax Rate (%) 24.9 26.0 25.6 Net Working Capital Days (Nos) 46.2 48.3 45.2 PAT 235.3 178.6 238.1 Net Working Capital to Sales (%) 46.2 48.3 45.2 Working (%) 38.1 25.0 27.9 Valuation (X) 7.0 7.0 Net Profit 235.3 175.0 175.0 EV/EBITDA 23.4 28.0 21.9 Margin (%) 38.1 24.5 20.5 EV/EBITDA 23.4 28.0 21.9 YoY Growth (%) 39.3 (25.7) (0.0 23.4 24.0 29.0 23.1 24.1 20.2 24.0 29.0 24.3 44.3	Exceptional Item	0.0	0.0	0.0				
YOY Growth (%) 46.7 (23.0) 32.7 Receivable Days (Nos) 105 119 117 Tax Expense 77.8 62.6 81.9 Net Working Capital Days (Nos) 169 176 165 Tax Rate (%) 24.9 26.0 25.6 Net Working Capital to Sales (%) 46.2 48.3 45.2 PAT 235.3 178.6 238.1 178.6 238.1 178.6 238.1 178.6 238.1 178.6 238.1 44.3	PBT	313.2	241.2	320.1	Payable Days <mark>(Nos)</mark>	27	43	36
Tax Expense 77.8 62.6 81.9 Net Working Capital Days (Nos) 169 176 165 Tax Rate (%) 24.9 26.0 25.6 Net Working Capital to Sales (%) 46.2 48.3 45.2 PAT 235.3 178.6 238.1 Verify Capital To Sales (%) 46.2 48.3 45.2 Morgin (%) 38.1 25.0 27.9 Valuation (X) 7.0<	Margin (%)	50.8	33.8	37.5	Inventory Days (Nos)	91	100	83
Tax Rate (%) 24.9 26.0 25.6 Net Working Capital to Sales (%) 46.2 48.3 45.2 PAT 235.3 178.6 238.1 Valuation (X) 17.0 <t< td=""><td>YoY Growth (%)</td><td>46.7</td><td>(23.0)</td><td>32.7</td><td>Receivabl<mark>e Days (Nos)</mark></td><td>105</td><td>119</td><td>117</td></t<>	YoY Growth (%)	46.7	(23.0)	32.7	Receivabl <mark>e Days (Nos)</mark>	105	119	117
PAT 235.3 178.6 238.1 Margin (%) 38.1 25.0 27.9 Valuation (X) Yor Growth (%) 39.3 (24.1) 33.4 P/E 32.9 44.3 44.3 Min Int/Sh of Assoc 0.0 (3.6) (63.2) P/BV 7.8 7.0 7.0 Net Profit 235.3 175.0 175.0 EV/EBITDA 23.4 28.0 21.9 Margin (%) 38.1 24.5 20.5 EV/Sales 12.4 10.8 8.9 Yor Growth (%) 39.3 (25.7) (0.0) Cash Flow Statement 12.4 10.8 8.9 Share Capital 9.5 9.5 10.5 Adjustments (7.2) 88.3 49.5 Total Reserves 98.9 1,093.7 1,093.7 Change in Working Capital (61.3) (59.4) (41.6) Share Capital 9.5 9.5 10.5 Adjustments (7.2) 88.3 49.5 Total Reserves 98.9 1,093.7	Tax Expense	77.8	62.6	81.9	Net Working Capital Days (Nos)	169	176	165
Margin (%) 38.1 25.0 27.9 Valuation (X) YoY Growth (%) 39.3 (24.1) 33.4 P/E 32.9 44.3 44.3 Min Int/Sh of Assoc 0.0 (3.6) (63.2) P/BV 7.8 7.0 7.0 Net Profit 235.3 175.0 EV/EBITDA 23.4 28.0 21.9 Margin (%) 38.1 24.5 20.5 EV/Sales 12.4 10.8 8.9 YOY Growth (%) 39.3 (25.7) (0.0) Cash Flow Statement 12.4 10.8 8.9 Share Capital 9.5 9.5 10.5 Adjustments (7.2) 88.3 49.5 Total Reserves 98.9 1,093.7 1,093.7 Change in Working Capital (61.3) (59.4) (41.6) Share Capital 9.5 9.5 10.5 Adjustments (7.2) 88.3 49.5 Total Reserves 989.9 1,093.7 1,093.7 Change in Working Capital (61.3) (52.1) <t< td=""><td>Tax Rate (%)</td><td>24.9</td><td>26.0</td><td>25.6</td><td>Net Working Capital to Sales (%)</td><td>46.2</td><td>48.3</td><td>45.2</td></t<>	Tax Rate (%)	24.9	26.0	25.6	Net Working Capital to Sales (%)	46.2	48.3	45.2
VoY Growth (%) 39.3 (24.1) 33.4 P/E 32.9 44.3 44.3 Min Int/Sh of Assoc 0.0 (3.6) (63.2) P/BV 7.8 7.0 7.0 Net Profit 235.3 175.0 175.0 EV/EBITDA 23.4 28.0 21.9 Margin (%) 38.1 24.5 20.5 EV/Sales 12.4 10.8 8.9 YoY Growth (%) 39.3 (25.7) (0.0) Cash Flow Statement 12.4 10.8 8.9 Share Capital 9.5 9.5 10.5 Adjustments (7.2) 88.3 49.5 Total Reserves 989.9 1,03.2 1,104.2 Less: Tax Paid (7.2) 88.3 49.5 Shareholders Fund 999.4 1,103.2 1,104.2 Less: Tax Paid (7.2) 88.3 49.5 Change Term Borrowings 56.3 31.2 6.2 Cash Flow from Operations 166.8 207.5 246.0 Deferred Tax Assets / Liabilities 1.6 0.3 <td>PAT</td> <td>235.3</td> <td>178.6</td> <td>238.1</td> <td></td> <td></td> <td></td> <td></td>	PAT	235.3	178.6	238.1				
Min Int/Sh of Assoc 0.0 (3.6) (63.2) (Margin (%)	38.1	25.0	27.9	Va <mark>luation (X)</mark>			
Net Profit 235.3 175.0 EV/EBITDA 23.4 28.0 21.9 Margin (%) 38.1 24.5 20.5 EV/Sales 12.4 10.8 8.9 YOY Growth (%) 39.3 (25.7) (0.0) Cash Flow Statement 12.4 10.8 8.9 Balance Sheet PBT 313.2 241.2 320.1 Share Capital 9.5 9.5 10.5 Adjustments (7.2) 88.3 49.5 Total Reserves 98.9 1,093.7 1,093.7 Change in Working Capital (61.3) (59.4) (41.6) Shareholders Fund 99.4 1,103.2 1,104.2 Less: Tax Paid (77.8) (62.6) (81.9) Long Term Borrowings 56.3 31.2 6.2 Cash Flow from Operations 166.8 207.5 246.0 Other Long Term Liabilities 1.6 0.3 0.2 Cash Flow from Operations 16.5 4.7 (12.9) Long Term Provisions 2.1 1.9 1.9 <		39.3	(24.1)	33.4	P/E	32.9	44.3	44.3
Margin (%) 38.1 24.5 20.5 EV/Sales 12.4 10.8 8.9 YOY Growth (%) 39.3 (25.7) (0.0) Balance Sheet PBT 313.2 241.2 320.1 Share Capital 9.5 9.5 10.5 Adjustments (7.2) 88.3 49.5 Total Reserves 989.9 1,093.7 1,093.7 Change in Working Capital (61.3) (59.4) (41.6) Shareholders Fund 999.4 1,103.2 1,104.2 Less: Tax Paid (77.8) (62.6) (81.9) Long Term Borrowings 56.3 31.2 6.2 Cash Flow from Operations 166.8 207.5 246.0 Deferred Tax Assets / Liabilities 1.5 21.0 23.4 Net Capital Expenditure (204.2) (155.4) (145.1) Other Long Term Liabilities 1.6 0.3 0.2 Change in Investments 9.0 43.7 (12.9) Long Term Provisions 2.1 1.9 1.9 Change in Borrowings 37.9	Min Int/Sh of Assoc	0.0	(3.6)	(63.2)	P/BV	7.8	7.0	7.0
YoY Growth (%) 39.3 (25.7) (0.0) Cash Flow Statement Balance Sheet PBT 313.2 241.2 320.1 Share Capital 9.5 9.5 10.5 Adjustments Adjustments (7.2) 88.3 49.5 Total Reserves 98.9 1,093.7 1,093.7 Change in Working Capital (61.3) (59.4) (41.6) (41.6) Shareholders Fund 999.4 1,103.2 1,104.2 Less: Tax Paid (77.8) (62.6) (81.9) (62.6) (81.9) Long Term Borrowings 56.3 31.2 6.2 Cash Flow from Operations 166.8 207.5 246.0 246.0 Deferred Tax Assets / Liabilities 17.5 21.0 23.4 Net Capital Expenditure (204.2) (155.4) (145.1) (145.1) Other Long Term Liabilities 1.6 0.3 0.2 Change in Investments 9.0 43.7 (12.9) (12.9) Long Term Provisions 2.1 1.9 1.9 Change in Borrowings 37.9 (23.5) (21.9) (21.1) Total Liabilities 1,076.8 1,157.6 1,135.9 Less: Finance Cost (1.0) (6.1) (9.8) Net Block 537.6 568.0 568.0 568.0 Proceeds from Equity 0.0 0.0 0.0 Capital Work in Progress 17.9 74.2 172.7 Buyback of Shares 0.0 0.0 0.0 Capital Work in Progress 17.9 74.2 172.7 Buyback of Shares<	Net Profit	235.3	175.0	175.0	EV/EBITDA	23.4	28.0	21.9
Cash Flow Statement Balance Sheet PBT 313.2 241.2 320.1 Share Capital 9.5 9.5 10.5 Adjustments (7.2) 88.3 49.5 Total Reserves 989.9 1,093.7 1,093.7 Change in Working Capital (61.3) (59.4) (41.6) Shareholders Fund 999.4 1,103.2 1,104.2 Less: Tax Paid (77.8) (62.6) (81.9) Long Term Borrowings 56.3 31.2 6.2 Cash Flow from Operations 166.8 207.5 246.0 Deferred Tax Assets / Liabilities 17.5 21.0 23.4 Net Capital Expenditure (204.2) (155.4) (145.1) Other Long Term Liabilities 1.6 0.3 0.2 Change in Investments 9.0 43.7 (12.9) Long Term Provisions 2.1 1.9 1.9 Change in Borrowings 37.9 (23.5) (21.9) Total Liabilities 1,076.8 1,157.6 1,135.9 Less: Finance Cost (1.0) (6.1)	Margin (%)	38.1	24.5	20.5	EV/Sales	12.4	10.8	8.9
Balance Sheet PBT 313.2 241.2 320.1 Share Capital 9.5 9.5 10.5 Adjustments (7.2) 88.3 49.5 Total Reserves 989.9 1,093.7 1,093.7 Change in Working Capital (61.3) (59.4) (41.6) Shareholders Fund 999.4 1,103.2 1,104.2 Less: Tax Paid (77.8) (62.6) (81.9) Long Term Borrowings 56.3 31.2 6.2 Cash Flow from Operations 166.8 207.5 246.0 Deferred Tax Assets / Liabilities 17.5 21.0 23.4 Net Capital Expenditure (204.2) (155.4) (145.1) Other Long Term Liabilities 1.6 0.3 0.2 Change in Investments 9.0 43.7 (12.9) Long Term Provisions 2.1 1.9 1.9 Change in Borrowings 37.9 (25.5) (21.9) Total Liabilities 1,076.8 1,157.6 1,135.9 Less: Finance Cost (1.0) (6.1) (9.8) Net Block	YoY Growth (%)	39.3	(25.7)	(0.0)				
Share Capital 9.5 9.5 10.5 Adjustments (7.2) 88.3 49.5 Total Reserves 98.9.9 1,093.7 1,093.7 Change in Working Capital (61.3) (59.4) (41.6) Shareholders Fund 999.4 1,103.2 1,104.2 Less: Tax Paid (77.8) (62.6) (81.9) Long Term Borrowings 56.3 31.2 6.2 Cash Flow from Operations 166.8 207.5 246.0 Deferred Tax Assets / Liabilities 17.5 21.0 23.4 Net Capital Expenditure (204.2) (155.4) (145.1) Other Long Term Liabilities 1.6 0.3 0.2 Change in Investments 9.0 43.7 (12.9) Long Term Trade Payables 0.0 0.0 Cash Flow from Investing (195.2) (11.8) (157.9) Long Term Provisions 2.1 1.9 1.9 Change in Borrowings 37.9 (23.5) (21.9) Total Liabilities 1,076.8 1,157.6 1,135.9 Less: Finance Cost (1.0) (6.1) </td <td></td> <td></td> <td></td> <td></td> <td>Cash Flow Statement</td> <td></td> <td></td> <td></td>					Cash Flow Statement			
Total Reserves 989.9 1,093.7 1,093.7 Change in Working Capital (61.3) (59.4) (41.6) Shareholders Fund 999.4 1,103.2 1,104.2 Less: Tax Paid (77.8) (62.6) (81.9) Long Term Borrowings 56.3 31.2 6.2 Cash Flow from Operations 166.8 207.5 246.0 Deferred Tax Assets / Liabilities 17.5 21.0 23.4 Net Capital Expenditure (204.2) (155.4) (145.1) Other Long Term Liabilities 1.6 0.3 0.2 Change in Investments 9.0 43.7 (12.9) Long Term Trade Payables 0.0 0.0 Cash Flow from Investing (195.2) (111.8) (157.9) Long Term Provisions 2.1 1.9 1.9 Change in Borrowings 37.9 (23.5) (21.9) Total Liabilities 1,076.8 1,157.6 1,135.9 Less: Finance Cost (1.0) (6.1) (9.8) Net Block 537.6 568.0 568.0 Proceeds from Equity 0.0 <	Balance Sheet				PBT	313.2	241.2	320.1
Shareholders Fund 999.4 1,103.2 1,104.2 Less: Tax Paid (77.8) (62.6) (81.9) Long Term Borrowings 56.3 31.2 6.2 Cash Flow from Operations 166.8 207.5 246.0 Deferred Tax Assets / Liabilities 17.5 21.0 23.4 Net Capital Expenditure (204.2) (155.4) (145.1) Other Long Term Liabilities 1.6 0.3 0.2 Change in Investments 9.0 43.7 (12.9) Long Term Trade Payables 0.0 0.0 Cash Flow from Investing (195.2) (111.8) (157.9) Long Term Provisions 2.1 1.9 1.9 Change in Borrowings 37.9 (23.5) (21.9) Total Liabilities 1,076.8 1,157.6 1,135.9 Less: Finance Cost (1.0) (6.1) (9.8) Net Block 537.6 568.0 568.0 Proceeds from Equity 0.0 0.0 0.0 Capital Work in Progress 17.9 74.2 172.7 Buyback of Shares 0.0 0.0	Share Capital	9.5	9.5	10.5	Adjustments	(7.2)	88.3	49.5
Long Term Borrowings 56.3 31.2 6.2 Cash Flow from Operations 166.8 207.5 246.0 Deferred Tax Assets / Liabilities 17.5 21.0 23.4 Net Capital Expenditure (204.2) (155.4) (145.1) Other Long Term Liabilities 1.6 0.3 0.2 Change in Investments 9.0 43.7 (12.9) Long Term Trade Payables 0.0 0.0 Cash Flow from Investing (195.2) (111.8) (157.9) Long Term Provisions 2.1 1.9 1.9 Change in Borrowings 37.9 (23.5) (21.9) Total Liabilities 1,076.8 1,157.6 1,135.9 Less: Finance Cost (1.0) (6.1) (9.8) Net Block 537.6 568.0 568.0 Proceeds from Equity 0.0 0.0 0.0 Capital Work in Progress 17.9 74.2 172.7 Buyback of Shares 0.0 0.0 0.0 Intangible assets under development 0.0 0.0 Dividend Paid (5.7) (70.5) (53.6)<	Total Reserves	989.9	1,093.7	1,093.7	Change in Working Capital	(61.3)	(59.4)	(41.6)
Deferred Tax Assets / Liabilities 17.5 21.0 23.4 Net Capital Expenditure (204.2) (155.4) (145.1) Other Long Term Liabilities 1.6 0.3 0.2 Change in Investments 9.0 43.7 (12.9) Long Term Trade Payables 0.0 0.0 0.0 Cash Flow from Investing (195.2) (111.8) (157.9) Long Term Provisions 2.1 1.9 1.9 Change in Borrowings 37.9 (23.5) (21.9) Total Liabilities 1,076.8 1,157.6 1,135.9 Less: Finance Cost (1.0) (6.1) (9.8) Net Block 537.6 568.0 568.0 Proceeds from Equity 0.0 0.0 0.0 Capital Work in Progress 17.9 74.2 172.7 Buyback of Shares 0.0 0.0 0.0 Intangible assets under development 0.0 0.0 Dividend Paid (5.7) (70.5) (53.6) Non Current Investments 8.9 4.9 4.9 Cash flow from Financing 31.1 (100.2) </td <td>Shareholders Fund</td> <td>999.4</td> <td>1,103.2</td> <td>1,104.2</td> <td>Less: Tax Paid</td> <td>(77.8)</td> <td>(62.6)</td> <td>(81.9)</td>	Shareholders Fund	999.4	1,103.2	1,104.2	Less: Tax Paid	(77.8)	(62.6)	(81.9)
Other Long Term Liabilities 1.6 0.3 0.2 Change in Investments 9.0 43.7 (12.9) Long Term Trade Payables 0.0 0.0 0.0 Cash Flow from Investing (195.2) (111.8) (157.9) Long Term Provisions 2.1 1.9 1.9 Change in Borrowings 37.9 (23.5) (21.9) Total Liabilities 1,076.8 1,157.6 1,135.9 Less: Finance Cost (1.0) (6.1) (9.8) Net Block 537.6 568.0 568.0 Proceeds from Equity 0.0 0.0 0.0 Capital Work in Progress 17.9 74.2 172.7 Buyback of Shares 0.0 0.0 0.0 Intangible assets under development 0.0 0.0 Dividend Paid (5.7) (70.5) (53.6) Non Current Investments 8.9 4.9 4.9 Cash flow from Financing 31.1 (100.2) (85.2) Long Term Loans & Advances 10.8 29.5 29.5 Net Cash Flow 2.7 (4.5) 2.8	Long Term Borrowings	56.3	31.2	6.2	Cash Flow from Operations	166.8	207.5	246.0
Long Term Trade Payables 0.0 0.0 0.0 Cash Flow from Investing (195.2) (111.8) (157.9) Long Term Provisions 2.1 1.9 1.9 Change in Borrowings 37.9 (23.5) (21.9) Total Liabilities 1,076.8 1,157.6 1,135.9 Less: Finance Cost (1.0) (6.1) (9.8) Net Block 537.6 568.0 568.0 Proceeds from Equity 0.0 0.0 0.0 Capital Work in Progress 17.9 74.2 172.7 Buyback of Shares 0.0 0.0 0.0 Intangible assets under development 0.0 0.0 Dividend Paid (5.7) (70.5) (53.6) Non Current Investments 8.9 4.9 4.9 Cash flow from Financing 31.1 (100.2) (85.2) Long Term Loans & Advances 10.8 29.5 29.5 Net Cash Flow 2.7 (4.5) 2.8 Other Non Current Assets 0.5 3.0 3.0 Forex Effect 0.0 0.0 0.0 <	Deferred Tax Assets / Liabilities	17.5	21.0	23.4	Net Capital Expenditure	(204.2)	(155.4)	(145.1)
Long Term Provisions 2.1 1.9 1.9 Change in Borrowings 37.9 (23.5) (21.9) Total Liabilities 1,076.8 1,157.6 1,135.9 Less: Finance Cost (1.0) (6.1) (9.8) Net Block 537.6 568.0 568.0 Forceeds from Equity 0.0 0.0 0.0 Capital Work in Progress 17.9 74.2 172.7 Buyback of Shares 0.0 0.0 0.0 Intangible assets under development 0.0 0.0 0.0 Dividend Paid (5.7) (70.5) (53.6) Non Current Investments 8.9 4.9 4.9 Cash flow from Financing 31.1 (100.2) (85.2) Long Term Loans & Advances 10.8 29.5 29.5 Net Cash Flow 2.7 (4.5) 2.8 Other Non Current Assets 0.5 3.0 3.0 Forex Effect 0.0 0.0 0.0 Net Current Assets 501.1 478.1 357.8 Opening Balance of Cash 2.4 5.1 0.7 <td>Other Long Term Liabilities</td> <td>1.6</td> <td>0.3</td> <td>0.2</td> <td>Change in Investments</td> <td>9.0</td> <td>43.7</td> <td>(12.9)</td>	Other Long Term Liabilities	1.6	0.3	0.2	Change in Investments	9.0	43.7	(12.9)
Total Liabilities 1,076.8 1,157.6 1,135.9 Less: Finance Cost (1.0) (6.1) (9.8) Net Block 537.6 568.0 568.0 Proceeds from Equity 0.0 0.0 0.0 Capital Work in Progress 17.9 74.2 172.7 Buyback of Shares 0.0 0.0 0.0 Intangible assets under development 0.0 0.0 Dividend Paid (5.7) (70.5) (53.6) Non Current Investments 8.9 4.9 4.9 Cash flow from Financing 31.1 (100.2) (85.2) Long Term Loans & Advances 10.8 29.5 29.5 Net Cash Flow 2.7 (4.5) 2.8 Other Non Current Assets 0.5 3.0 3.0 Forex Effect 0.0 0.0 0.0 Net Current Assets 501.1 478.1 357.8 Opening Balance of Cash 2.4 5.1 0.7	Long Term Trade Payables	0.0	0.0	0.0	Cash Flow from Investing	(195.2)	(111.8)	(157.9)
Net Block 537.6 568.0 568.0 Proceeds from Equity 0.0 0.0 0.0 Capital Work in Progress 17.9 74.2 172.7 Buyback of Shares 0.0 0.0 0.0 Intangible assets under development 0.0 0.0 0.0 Dividend Paid (5.7) (70.5) (53.6) Non Current Investments 8.9 4.9 4.9 Cash flow from Financing 31.1 (100.2) (85.2) Long Term Loans & Advances 10.8 29.5 29.5 Net Cash Flow 2.7 (4.5) 2.8 Other Non Current Assets 0.5 3.0 3.0 Forex Effect 0.0 0.0 0.0 Net Current Assets 501.1 478.1 357.8 Opening Balance of Cash 2.4 5.1 0.7	Long Term Provisions	2.1	1.9	1.9	Change in Borrowings	37.9	(23.5)	(21.9)
Capital Work in Progress 17.9 74.2 172.7 Buyback of Shares 0.0 0.0 0.0 Intangible assets under development 0.0 0.0 0.0 Dividend Paid (5.7) (70.5) (53.6) Non Current Investments 8.9 4.9 4.9 Cash flow from Financing 31.1 (100.2) (85.2) Long Term Loans & Advances 10.8 29.5 29.5 Net Cash Flow 2.7 (4.5) 2.8 Other Non Current Assets 0.5 3.0 3.0 Forex Effect 0.0 0.0 0.0 Net Current Assets 501.1 478.1 357.8 Opening Balance of Cash 2.4 5.1 0.7	Total Liabilities	1,076.8	1,157.6	1,135.9	Less: Finance Cost	(1.0)	(6.1)	(9.8)
Intangible assets under development 0.0 0.0 0.0 Dividend Paid (5.7) (70.5) (53.6) Non Current Investments 8.9 4.9 4.9 Cash flow from Financing 31.1 (100.2) (85.2) Long Term Loans & Advances 10.8 29.5 29.5 Net Cash Flow 2.7 (4.5) 2.8 Other Non Current Assets 0.5 3.0 3.0 Forex Effect 0.0 0.0 0.0 Net Current Assets 501.1 478.1 357.8 Opening Balance of Cash 2.4 5.1 0.7	Net Block	537.6	568.0	568.0	Proceeds from Equity	0.0	0.0	0.0
Non Current Investments 8.9 4.9 4.9 Cash flow from Financing 31.1 (100.2) (85.2) Long Term Loans & Advances 10.8 29.5 29.5 Net Cash Flow 2.7 (4.5) 2.8 Other Non Current Assets 0.5 3.0 3.0 Forex Effect 0.0 0.0 0.0 Net Current Assets 501.1 478.1 357.8 Opening Balance of Cash 2.4 5.1 0.7	Capital Work in Progress	17.9	74.2	172.7	Buyback of Shares	0.0	0.0	0.0
Long Term Loans & Advances 10.8 29.5 29.5 Net Cash Flow 2.7 (4.5) 2.8 Other Non Current Assets 0.5 3.0 3.0 Forex Effect 0.0 0.0 0.0 Net Current Assets 501.1 478.1 357.8 Opening Balance of Cash 2.4 5.1 0.7	Intangible assets under development	0.0	0.0	0.0	Dividend Paid	(5.7)	(70.5)	(53.6)
Other Non Current Assets 0.5 3.0 3.0 Forex Effect 0.0 0.0 0.0 Net Current Assets 501.1 478.1 357.8 Opening Balance of Cash 2.4 5.1 0.7	Non Current Investments	8.9	4.9	4.9	Cash flow from Financing	31.1	(100.2)	(85.2)
Net Current Assets 501.1 478.1 357.8 Opening Balance of Cash 2.4 5.1 0.7	Long Term Loans & Advances	10.8	29.5	29.5	Net Cash Flow	2.7	(4.5)	2.8
	Other Non Current Assets	0.5	3.0	3.0	Forex Effect	0.0	0.0	0.0
	Net Current Assets	501.1	478.1	357.8	Opening Balance of Cash	2.4	5.1	0.7
	Total Assets	1,076.8	1,157.6	1,135.9	Closing Balance of Cash	5.1	0.7	3.5

Source: Ventura Research



CONCORD BIOTECH

Biotech for Mankind...

Disclosures and Disclaimer

Ventura Securities Limited (VSL) is a SEBI registered intermediary offering broking, depository and portfolio management services to clients. VSL is member of BSE, NSE and MCX-SX. VSL is a depository participant of NSDL. VSL states that no disciplinary action whatsoever has been taken by SEBI against it in last five years except administrative warning issued in connection with technical and venial lapses observed while inspection of books of accounts and records. Ventura Commodities Limited, Ventura Guaranty Limited, Ventura Insurance Brokers Limited and Ventura Allied Services Private Limited are associates of VSL. Research Analyst (RA) involved in the preparation of this research report and VSL disclose that neither RA nor VSL nor its associates (i) have any financial interest in the company which is the subject matter of this research report (ii) holds ownership of one percent or more in the securities of subject company (iii) have any material conflict of interest at the time of publication of this research report (iv) have received any compensation from the subject company in the past twelve months (v) have managed or co-managed public offering of securities for the subject company in past twelve months (vi) have received any compensation for investment banking merchant banking or brokerage services from the subject company in the past twelve months (vii) have received any compensation for product or services from the subject company in the past twelve months (viii) have received any compensation or other benefits from the subject company or third party in connection with the research report. RA involved in the preparation of this research report discloses that he / she has not served as an officer, director or employee of the subject company. RA involved in the preparation of this research report and VSL discloses that they have not been engaged in the market making activity for the subject company. Our sales people, dealers, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein. We may have earlier issued or may issue in future reports on the companies covered herein with recommendations/ information inconsistent or different those made in this report. In reviewing this document, you should be aware that any or all of the foregoing, among other things, may give rise to or potential conflicts of interest. We may rely on information barriers, such as "Chinese Walls" to control the flow of information contained in one or more areas within us, or other areas, units, groups or affiliates of VSL. This report is for information purposes only and this document/material should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities, and neither this document nor anything contained herein shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. This document does not solicit any action based on the material contained herein. It is for the general information of the clients / prospective clients of VSL. VSL will not treat recipients as clients by virtue of their receiving this report. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of clients / prospective clients. Similarly, this document does not have regard to the specific investment objectives, financial situation/circumstances and the particular needs of any specific person who may receive this document. The securities discussed in this report may not be suitable for all investors. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. Persons who may receive this document should consider and independently evaluate whether it is suitable for his/her/their particular circumstances and, if necessary, seek professional/financial advice. And such person shall be responsible for conducting his/her/their own investigation and analysis of the information contained or referred to in this document and of evaluating the merits and risks involved in the securities forming the subject matter of this document. The projections and forecasts described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. Projections and forecasts are necessarily speculative in nature, and it can be expected that one or more of the estimates on which the projections and forecasts were based will not materialize or will vary significantly from actual results, and such variances will likely increase over time. All projections and forecasts described in this report have been prepared solely by the authors of this report independently of the Company. These projections and forecasts were not prepared with a view toward compliance with published guidelines or generally accepted accounting principles. No independent accountants have expressed an opinion or any other form of assurance on these projections or forecasts. You should not regard the inclusion of the projections and forecasts described herein as a representation or warranty by VSL, its associates, the authors of this report or any other person that these projections or forecasts or their underlying assumptions will be achieved. For these reasons, you should only consider the projections and forecasts described in this report after carefully evaluating all of the information in this report, including the assumptions underlying such projections and forecasts. The price and value of the investments referred to in this document/material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance. Future returns are not guaranteed and a loss of original capital may occur. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. We do not provide tax advice to our clients, and all investors are strongly advised to consult regarding any potential investment. VSL, the RA involved in the preparation of this research report and its associates accept no liabilities for any loss or damage of any kind arising out of the use of this report. This report/document has been prepared by VSL, based upon information available to the public and sources, believed to be reliable. No representation or warranty, express or implied is made that it is accurate or complete. VSL has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. The opinions expressed in this document/material are subject to change without notice and have no obligation to tell you when opinions or information in this report change. This report or recommendations or information contained herein do/does not constitute or purport to constitute investment advice in publicly accessible media and should not be reproduced, transmitted or published by the recipient. The report is for the use and consumption of the recipient only. This publication may not be distributed to the public used by the public media without the express written consent of VSL. This report or any portion hereof may not be printed, sold or distributed without the written consent of VSL. This document does not constitute an offer or invitation to subscribe for or purchase or deal in any securities and neither this document nor anything contained herein shall form the basis of any contract or commitment whatsoever. This document is strictly confidential and is being furnished to you solely for your information, may not be distributed to the press or other media and may not be reproduced or redistributed to any other person. The opinions and projections expressed herein are entirely those of the author and are given as part of the normal research activity of VSL and are given as of this date and are subject to change without notice. Any opinion estimate or projection herein constitutes a view as of the date of this report and there can be no assurance that future results or events will be consistent with any such opinions, estimate or projection. This document has not been prepared by or in conjunction with or on behalf of or at the instigation of, or by arrangement with the company or any of its directors or any other person. Information in this document must not be relied upon as having been authorized or approved by the company or its directors or any other person. Any opinions and projections contained herein are entirely those of the authors. None of the company or its directors or any other person accepts any liability whatsoever for any loss arising from any use of this document or its contents or otherwise arising in connection therewith. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Securities Market.

Ventura Securities Limited - SEBI Registration No.: INH000001634

Corporate Office: I-Think Techno Campus, 8th Floor, 'B' Wing, Off Pokhran Road No 2, Eastern Express Highway, Thane (W) – 400608